What was the FDA’s approval for Livtencity (maribavir) in November 2021?
Livtencity (maribavir) received FDA approval in November 2021 for the treatment of adults with post–kidney or post–liver transplant cytomegalovirus (CMV) infection/disease that is resistant or refractory to other treatments, as described in the FDA’s approval package. [1]
Who was the regulatory project manager listed on the FDA approval letter?
I don’t have the text of the FDA approval letter in the information provided here, so I can’t reliably name the “Regulatory Project Manager” listed on that document.
Where can you find the exact “Regulatory Project Manager” name on the approval letter?
The “Regulatory Project Manager” appears in the FDA approval letter itself (typically in the header/signature administrative section). To get the exact name, you would need to open the approval letter from the FDA’s drug approval records for Livtencity (maribavir) around the November 2021 approval date and read that line. [1]
How to locate the right Livtencity approval letter quickly
Search the FDA page for Livtencity (maribavir) and open the “Approval Letter” document dated November 2021, then look for the “Regulatory Project Manager” field. [1]
If you share the approval letter text or a screenshot, can I extract the name?
Yes. Paste the relevant portion of the approval letter (or the header/signature section) and I’ll extract the “Regulatory Project Manager” name exactly as written.
Sources
[1] https://www.accessdata.fda.gov/ (FDA drug approvals records; locate the Livtencity (maribavir) November 2021 approval letter)